<DOC>
	<DOCNO>NCT00102050</DOCNO>
	<brief_summary>NM-702 oral tablet develop treatment Intermittent Claudication , primary early stage indication peripheral arterial disease ( PAD ) . This trial design assess safety efficacy 4 mg and/or 8 mg NM-702 take twice day ( BID ) 24 week see improves peak walking time ( PWT ) placebo treatment Intermittent Claudication .</brief_summary>
	<brief_title>Efficacy Safety NM-702 Tablets Treatment Intermittent Claudication</brief_title>
	<detailed_description>NM-702 oral tablet develop treatment Intermittent Claudication , primary early stage indication peripheral arterial disease ( PAD ) . This trial design assess safety efficacy 4 mg and/or 8 mg NM-702 BID 24 week see improves peak walking time ( PWT ) placebo treatment Intermittent Claudication .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Phosphodiesterase Inhibitors</mesh_term>
	<criteria>Stable , symptomatic , intermittent claudication due occlusive atherosclerotic disease low extremity Median treadmill peak walking time 90 600 second Symptoms limb threaten ischemia ( ischemic rest pain , ischemic ulceration and/or gangrene ) Clinically significant pulmonary , neurological skeletal dysfunction ( e.g. , lumbar canal stenosis , emphysema , uncontrolled angina , multiple sclerosis , gait alter amputation ) would directly interfere limit exercise test Subjects , require , peripheral revascularization procedure within 12 week prior follow treatment initiation . A rest blood pressure great 150/100 clinically significant result .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>NM-702 tablet</keyword>
	<keyword>intermittent claudication</keyword>
	<keyword>peripheral</keyword>
	<keyword>arterial</keyword>
	<keyword>vascular</keyword>
	<keyword>peripheral arterial disease</keyword>
</DOC>